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Abstract 
CD47 is a ubiquitously expressed immunoregulatory protein best known for its so-called 'don't eat me' function 
that prevents phagocytic removal of healthy cells by the immune system. Many types of cancer present high levels 
of this don't eat me signal on their surface, thereby disrupting anti-cancer immune responses. Based on this 
observation, CD47 has become a prominent target in the field of cancer immunotherapy. Indeed, pre-clinical 
studies have shown therapeutic benefit of anti-CD47 antibodies in solid cancers and most notably B-cell 
malignancies. However, CD47 is also involved in various other important cellular processes, such as angiogenesis, 
cancer cell death and regulation of T-cell immunity, which can be modulated via interactions with 
thrombospondin-1. The therapeutic outcome of CD47-targeted immunotherapy therefore relies on the combined 
effects of all these processes. Here we will review the various physiological functions of CD47 and their 
implications in cancer biology. Further, we will review ongoing efforts and provide perspectives for exploiting 
CD47 as an immunotherapeutic target in cancer. 
Keywords: CD47; Signal regulatory protein α (SIRP α); Thrombospondin-1 (TSP-1); cancer (immune) therapy; 
phagocytosis; angiogenesis. 
Introduction 
CD47 is a 50 kDa transmembrane immunoglobulin 
protein comprising a heavily glycosylated N-
terminal IgV domain followed by a pentaspanin 
transmembrane domain and a short cytoplasmic tail 
(Lindberg et al., 1993). CD47 is best known for its 
pivotal role in preventing phagocytic removal of 
healthy cells by binding to phagocyte-expressed 
signal regulatory protein alpha (SIRPα). SIRPα is an 
inhibitory receptor that, once triggered, suppresses 
phagocytosis. This CD47/SIRPα axis is an important 
homeostatic mechanism preventing removal of 
healthy normal cells that express CD47. Reversely, 
down-regulation of CD47 on damaged, aged and 
superfluous cells ensures their timely removal. This 
function of CD47 in cellular turn-over was first 
established in red blood cells almost 2 decades ago 
and is now held to be a general homeostatic system 
(Oldenborg et al., 2000). Both solid and hematologic 
malignancies overexpress CD47 and, thereby, 
essentially hijack this homeostatic system to evade 
phagocytic clearance (Jaiswal et al., 2009; Chao et 
al., 2011b; Jaiswal et al., 2009; Chao et al., 2010a; 
Chao et al., 2011a; Zhao et al., 2011; Willingham et 
al., 2012; Rendtlew Danielsen et al., 2007; Edris et 
al., 2012). Therapeutic interventions that block 
CD47-SIRPα interaction have been found to 
promote phagocytic elimination of such CD47 
overexpressing tumor cells and are poised for 
clinical evaluation (Chao et al., 2010a; Tseng et al., 
2013; Theocharides et al., 2012; Majeti et al., 2009; 
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Chao et al., 2011b; Chao et al., 2011a; Willingham 
et al., 2012; Edris et al., 2012). CD47 also impacts 
on various other biological processes via binding to 
alternate receptors or due to signaling through its 
intracellular cytoplasmic domain. For instance, 
interaction of CD47 with thrombospondin-1 (TSP-1) 
or vascular endothelial growth factor receptor 2 
(VEGFR2) inhibits angiogenesis and thereby limits 
tumor growth. Further, cross-linking of CD47 
expressed on tumor cells via e.g. TSP-1 can directly 
induce cell death in breast cancer cells and leukemia 
(Mateo et al., 1999; Saumet et al., 2005; Manna and 
Frazier, 2004). Finally, CD47 expressed on immune 
cells can both positively and negatively regulates 
immunity, i.e. innate immune cells such as 
neutrophils, as well as adaptive immunity, i.e. DC 
maturation and T-cell activity. Thus, CD47 has a 
complex and multifactorial role in anti-cancer 
immunity and cancer biology (figure 1). 
Correspondingly, the outcome of therapeutic 
targeting of CD47 will depend on expression, 
binding affinity and relative levels of its diverse 
ligands. In this review, we will first review 
expression patterns of CD47 and its binding partners 
in normal tissue and cancer. Second, we will discuss 
the multi-facetted biological effect of CD47 and its 
ligands in cancer and immunity. Further, we will 
discuss the current state-of-the-art as well as identify 
challenges and opportunities CD47 as target in 
cancer (immuno)therapy. 
Tissue distribution and 
regulation of CD47 and binding 
partners 
Expression of CD47 in normal cells and cancer 
CD47 is expressed on almost all normal human cells, 
as evaluated by mRNA expression and 
immunohistochemical staining, and occurs in four 
highly conserved isoforms that differ only in the 
length of their cytoplasmic domain, ranging from 3 
to 36 amino acids (Reinhold et al., 1995). These 
isoforms arise due to alternative splicing of the 
CD47 mRNA. Splice form 2 contains the second 
largest cytoplasmic tail and is most abundantly 
expressed, whereas neuronal tissue almost 
exclusively express splice form 4 (Reinhold et al., 
1995). Of note, the functional and clinical 
implications of the respective isoforms in normal 
biology as well as in cancer remain unclear. CD47 
was first identified as an antigen expressed on 
ovarian carcinoma (Poels et al., 1986), but is 
overexpressed in many solid tumors and 
hematologic malignancies (Jaiswal et al., 2009; 
Chao et al., 2010a; Chao et al., 2011a; Zhao et al., 
2011; Willingham et al., 2012; Rendtlew Danielsen 
et al., 2007; Edris et al., 2012). High levels of CD47 
are also found on human bladder tumor-initiating 
cells and leukemic stem cells (Majeti et al., 2009; 
Chan et al., 2009). Increased CD47 mRNA levels are 
an independent negative prognostic factor in 
multiple types of cancer (Majeti et al., 2009; Chao et 
al., 2010a; Chao et al., 2010a; Chao et al., 2011a; 
Willingham et al., 2012). Further, increased protein 
expression of CD47 associates with poor clinical 
outcome in among others ovarian cancer and 
glioblastoma, (Majeti et al., 2009; Chao et al., 2010a; 
Chao et al., 2011a; Willingham et al., 2012). 
Moreover, high CD47 levels associate with various 
adverse characteristics, such as developmental stage 
of the tumor, adverse molecular subtype, and 
resistance to therapy (Rendtlew Danielsen et al., 
2007; Chao et al., 2010a; Zhao et al., 2011; Edris et 
al., 2012). Interestingly, high levels of CD47 
expression in the bone marrow of breast cancer 
patients lead to a significant reduction in disease free 
survival (Nagahara et al., 2010). 
 
Figure 1: CD47 has a complex and multifactorial role in anti-cancer immunity and cancer biology. CD47 is involved in 
regulation of the activity of different immune cell types, and can induce direct cancer cell death when it is crosslinked. In addition, 
CD47 is involved in angiogenesis. All these aspects are discussed in this review. 
CD47, a multi-facetted target for cancer immunotherapy Wiersma VR, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(6) 419 
 
Expression of CD47 binding partners SIRPα and 
TSP-1 in normal cells and cancer 
The best characterized binding partner of CD47 is 
SIRPα (also termed CD172a or SHPS-1). SIRPα is a 
transmembrane protein consisting of three 
extracellular Ig-like domains, a transmembrane 
domain and an intracellular tail containing four 
immunoreceptor tyrosinebased inhibitory motifs 
(ITIMs) (Barclay and Van den Berg, 2014). SIRPα 
belongs to the signal regulatory protein receptor 
family, which is subdivided in a SIRPα and SIRPβ 
subgroup. Expression of SIRPα is restricted to 
phagocytes (macrophages, granulocytes and DCs) 
and neuronal cells (Fujioka et al., 1996). In addition 
to SIRPα, CD47 can bind to SIRPβ2 (also termed 
SIRPγ) albeit with a lower affinity than SIRPα 
(Piccio et al., 2005). SIRPβ2 is among others 
expressed on CD3-positive T-cells (Seiffert et al., 
2001). SIRPα expression in cancer has not been 
extensively evaluated, but in primary brain tumor 
biopsies and astrocytoma cell lines SIRPα 
expression was detected. Of note, this tumor 
expressed SIRPα was underglycosylated compared 
to SIRPα expressed on Chinese hamster ovary 
(CHO) cells (Chen et al., 2004), suggestive of a 
higher affinity for CD47 (see also section of 
posttranslational glycosylation below). In contrast to 
solid tumors, SIRPα is notably down-regulated in 
primary hematopoietic cells and myeloid blasts from 
AML patients (Seiffert et al., 1999). This down-
regulation may be related to the reported induction 
of apoptosis and growth inhibition by SIRPα in 
AML cells (Irandoust et al., 2013). Another 
important binding partner of CD47 is TSP-1, the first 
endogenous ligand identified for CD47. TSP-1 is a 
large matricellular and homotrimeric glycoprotein 
(430kDa) comprising at least six different structural 
domains of which the C-terminal domain binds to 
CD47 (Roberts, 2005). TSP-1 itself is a pleiotropic 
protein important for platelet aggregation, cell-cell 
and cell-matrix interactions, and negative regulation 
of (neo)vascularization. TSP-1 is secreted by various 
normal cell types, i.e. endothelial cells, smooth 
muscle cells and monocytes/macrophages. Further, 
TSP-1 is a major constituent of the extracellular 
matrix in normal tissues and cancer. Preclinical 
evidence suggests that there is an inverse correlation 
with a decrease in TSP-1 and an increase in CD47 
mRNA levels in a prostate cancer model (Vallbo and 
Damber, 2005). Similarly, TSP-1 expression is 
inversely correlated with malignant progression in 
preclinical models as well as in patients with various 
types of cancer, including melanoma, breast, lung 
and bladder cancer (Papadaki et al., 2009; Ioachim 
et al., 2012; Zabrenetzky et al., 1994; Grossfeld et 
al., 1997). In line with this, TSP-1 over-expression 
reduced the tumorigenic potential of human 
cutaneous squamous cell carcinoma (Streit et al., 
1999) and breast carcinoma (Weinstat-Saslow et al., 
1994). Of note, oncogenic transformation of the 
well-established tumor suppressor p53 negatively 
affects TSP-1 expression, with reduced TSP-1 
expression levels in ovarian carcinoma being 
associated with overexpression of p53 (Alvarez et 
al., 2001). Similarly, p53 mutation correlated with 
low TSP-1 levels in bladder cancer (Grossfeld et al., 
1997). Further, survival of p53-null/TSP-1-null mice 
was significantly reduced survival compared to TSP-
1-expressing p53-null mice due to naturally arising 
tumors (Lawler et al., 2001). Thus, TSP-1 has tumor 
suppressor activity in certain cancers and its 
expression may be deregulated by oncogenic p53 
mutation. 
Regulation of CD47 expression and activity 
Transcriptional control of the CD47 gene is 
incompletely understood and has only been studied 
in the context of neuronal development, where 
transcription of CD47 and concomitant neurite 
outgrowth relies on the transcription factor α-
Pal/NRF-1 (Chang and Huang, 2004; Chang et al., 
2005). Similarly, the mechanism underlying 
constitutive upregulation of CD47 during 
transformation and progression is as yet unclear, 
although CD47 can be transiently upregulated by 
mobilizing cytokines in hematopoietic stem cells 
(Jaiswal et al., 2009). The latter has been speculated 
to be a physiological response mechanism exploited 
by hematologic malignancies. CD47 expression is 
also subject to post-transcriptional regulation by 
micro RNAs (miRNAs). Aberrant overexpression of 
CD47 correlates with downregulation of miRNA-
133a in esophageal squamous cell carcinoma and 
colorectal cancer (Suzuki et al., 2012; Dong et al., 
2013). Reporter construct studies validated the 
ability of miR-133a to directly inhibit CD47 
transcription in vitro. Several other regulatory 
miRNAs were identified, i.e. miR-155 in multiple 
sclerosis (MS) and miR-141 in Hirschsprung's 
disease (Junker et al., 2009; Tang et al., 2013). Both 
miRs were found to target the 3'UTR of the CD47 
mRNA. In MS lesions, upregulation of microRNAs 
was proposed to reduce CD47 thereby releasing 
macrophages from inhibitory control and promoting 
phagocytosis of myelin (Junker et al., 2009). Further, 
hypermethylation of a CpG Island in the promoter 
region of miR-141 has been linked to increased 
expression of CD47 (Tang et al., 2013). CD47 is also 
subject to post-translational modifications, most 
notably glycosylation. CD47 has a number of N-
terminal glycosylation sites that directly affect cell 
surface display and regulate interaction with 
extracellular ligands. For instance, deglycosylated 
CD47 has a higher avidity for SIRPα than 
glycosylated CD47 and, vice versa, deglycosylated 
SIRPα has a higher avidity for CD47 (Subramanian 
et al., 2007; Subramanian et al., 2006). Reversely, 
hyperglycosylated SIRPα can disrupt CD47/SIRPα 
interactions (Ogura et al., 2004). Of note, site-
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directed mutagenesis of N-linked glycosylation sites 
inhibited cell surface localization of CD47 in yeast 
models (Parthasarathy et al., 2006), although similar 
mutagenesis did not affect membrane localization of 
human CD47 in CHO cells (Subramanian et al., 
2006). Aberrant glycosylation of either CD47 or 
SIRPα can also alter downstream responses, with 
differentially glycosylated SIRPα rendering B16 
melanoma cells resistant to CD47-induced inhibition 
of motility (Ogura et al., 2004). In addition, a heavily 
glycosylated (>250 kD) form of CD47 has been 
detected in primary and transformed T-cells, 
endothelial cells and vascular smooth muscle cells 
(Kaur et al., 2011). This modification was located 
distally from the SIRPα binding site, but was 
required for TSP-1 mediated inhibitory signaling in 
T-cells. Although not evaluated in the context of 
cancer as of yet, deregulation of these mechanisms 
may play a role in cancer pathogenesis. 
The diverse immunoregulatory 
effects of CD47 in cancer 
Controlling phagocytic activity through 
CD47/SIRPα interaction 
SIRPα is an important negative regulator of 
phagocyte activity that, upon binding by CD47 to its 
N-terminal IgV domain, is phosphorylated on ITIM 
motifs leading to concomitant activation of SHP-1 
and SHP-2 phosphatases (Hatherley et al., 2008; 
Kharitonenkov et al., 1997; Okazawa et al., 2005). 
Downstream events include inhibition of myosin IIA 
accumulation at the phagocytic synapse (Tsai and 
Discher, 2008) and suppression of respiratory burst 
in phagocytes (van Beek et al., 2012). In line with 
the hypothesis that CD47 overexpression suppresses 
phagocytosis, ectopic overexpression of CD47 in 
CD47lo MOLM-13 myeloid leukemia cells inhibited 
in vitro and in vivo phagocytosis and increased 
tumor outgrowth (Jaiswal et al., 2009). Reversely, 
dissemination of Raji NHL cells was strongly 
reduced after shRNA knockdown of CD47 (Chao et 
al., 2011b). In addition, disruption of CD47-SIRPα 
signaling by either mutagenesis of macrophage-
expressed SIRPα or by treatment with recombinant 
SIRPα-Fc eliminated AML xenografts 
(Theocharides et al., 2012). Thus, cancer cells 
escape from phagocytic removal by upregulation of 
CD47 expression, which inhibits myeloid cell 
activity by binding to SIRPα (figure 2A). 
Controlling T-cell differentiation through 
"reverse" CD47 signaling 
Whereas regulatory effects by CD47 on phagocytes 
is due to SIRPα signaling, regulatory effects on T-
cells mainly stem from signaling through T-cell 
expressed CD47. Specifically, CD47 binding by 
TSP-1 (or SIRPα) can also trigger CD47 intracellular 
signaling in immune cells and thereby affect the 
immunological outcome in cancer. Treatment of 
naïve T-cells (CD4+CD25-) with TSP-1 or an anti-
CD47 mAb upregulated expression of transcription 
factor FoxP3 and promoted the formation of 
regulatory T-cells (Tregs) (Grimbert et al., 2006; 
Baumgartner et al., 2008). Correspondingly, 
elevated serum TSP-1 levels positively correlated 
with the percentage of Tregs in peripheral blood of 
advanced melanoma patients (Baumgartner et al., 
2008).  
 
Figure 2: The diverse immunoregulatory effects of CD47. A. The interaction of CD47 (over) expressed on cancer cells with 
signal regulatory protein α (SIRPα) on phagocytes results in inhibition of phagocytosis. B. CD47 is also expressed on T-cells 
where it regulates diverse processes upon ligation by TSP-1 or anti-CD47 antibodies. Most of these are anti-inflammatory, as the 
differentiation of naïve T-cells into Th1 is inhibited, whereas Treg differentiation is induced. Further, binding of CD47 results in 
reduced proliferation or even T-cell death. However, depending on the context, CD47 ligation can also induce T-cell proliferation 
and activation. 
CD47 activation on naïve T-cells also inhibited the 
differentiation of these cells into T helper 1 (Th1) 
effector cells (Avice et al., 2000). Specifically, 
incubation of umbicilical cord blood mononuclear 
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cells with a CD47 antibody in the presence of Th1-
differentiating conditions (IL-12+anti-IL4 mAb) 
reduced both IFN-γ and IL-2 production. This 
inhibition was also obtained when using F(ab')2 
fragments of the CD47 mAb or an TSP-1 derived 
CD47-binding peptide. Mechanistically it was 
uncovered that the reduced Th1 differentiation upon 
CD47 ligation was caused by T-cell 
unresponsiveness toward IL-12 (Avice et al., 2000; 
Latour et al., 2001). In line with this, murine CD47-
/- T-cells had elevated levels of Th1-lineage 
transcription factor Tbet, leading to higher levels of 
IFNγ production and Th1 differentiation than CD47 
expressing cells, both in vitro and in vivo 
(Bouguermouh et al., 2008). Thus, CD47-signaling 
on T-cells has a two-fold effect, namely the 
enhanced differentiation of naïve T-cells into Tregs 
and reduced differentiation into Th1-cells (figure 
2B). Of note, Th1 cells are the most effective helper 
T-cells during anti-tumor immune responses that 
control development and persistence of cytotoxic 
tumor-specific T-cells (Knutson and Disis, 2005). 
Therefore, the anti-cancer effect of CD47-targeted 
agents may be partly attributable to CD47-mediated 
reduction in Treg formation and an enhanced 
induction of Th1 cells via T-cell expressed CD47. 
Controlling T-cell activity through "reverse" 
CD47 signaling 
CD47-signaling can have a diverse and paradoxical 
outcome ranging from induction of T-cell death to 
activation of T-cells. For instance, CD47 ligation 
e.g. through soluble or immobilized TSP-1 induced 
a state of T-cell anergy characterized by 
unresponsiveness to T-cell receptor (TCR) 
stimulation and a lack of proliferation and IL-2 
production (Avice et al., 2001; Li et al., 2001). In 
addition, CD47 ligation on T-cells can directly 
induce cell death, although contrasting data has been 
reported. Specifically, in one study anti-CD47 
antibodies did not affect resting T-cells, but induced 
cell death in anti-CD3 stimulated T-cells (Pettersen 
et al., 1999). Reversely, in a second study, resting T-
cells were sensitive toward CD47 crosslinking, 
whereas anti-CD3 T-activated T-cells proved 
resistant (Mateo et al., 2002). The reason for this 
discrepancy is not known, but might relate to 
different isolation methods and/or use of different 
soluble or cross-linked anti-CD3 mAbs. These 
studies indicate that CD47 ligation mainly serves to 
shut-down T-cell immune responses (figure 2B). 
However, CD47 can also act as T-cell co-stimulator 
leading to enhanced proliferation upon cross-linking 
of anti-CD47 and anti-CD3 antibodies (Reinhold et 
al., 1997; Waclavicek et al., 1997). Notably, the anti-
CD47 and anti-CD3 antibodies needed to be on the 
same surface, with a total lack of T-cell co-
stimulation when one or both antibodies were 
provided in solution. Hence, it was hypothesized that 
anti-CD47 antibodies mimick a co-stimulatory 
signal provided by antigen presenting cells like DCs. 
In line with this, a soluble anti-CD47 antibody 
inhibited T-cell proliferation in co-cultures of T-cells 
and monocyte-derived DCs (Waclavicek et al., 
1997). Further, in Jurkat leukemic T-cells interaction 
of CD47 with TSP-1 or SIRPα on inflammatory 
vascular endothelium induced recruitment of 
lymphocytes into inflammatory tissues (Ticchioni et 
al., 2001). Of note, CD47 was also recently reported 
to directly associate with vascular endothelial 
growth factor (VEGF) receptor-2 (VEGFR-2) 
expressed on T-cells (Kaur et al., 2014). In T-cells, 
VEGF induced VEGFR phosphorylation inhibits T-
cells proliferation and TCR signaling and thus acts 
as an inhibitory pathway. As also reported in 
endothelial cells (see anti-angiogenic effects via 
CD47), VEGFR-2/CD47 interaction was disrupted 
by TSP-1 or CD47 binding peptide. TSP-1 or the 
CD47 binding peptide blocked VEGFR 
phosphorylation in wildtype, but not CD47-/- T-cells. 
Of note, CD47 also regulated expression of both 
VEGF and VEGFR, with CD47-/- cells having 
significantly higher levels of both proteins. Thus, 
CD47 appears to control an autocrine feedback loop 
in T-cells involving VEGF and VEGFR. 
Controlling DC and neutrophil activity through 
"reverse" CD47 signaling 
Like most cells, DCs are also characterized by 
surface expression of CD47. DC-expressed CD47 
was found to be required for DC entry into lymphatic 
vessels and for DC migration under inflammatory 
conditions in mice (Van et al., 2006). Since pre-
treatment with CD47-Fc did not further inhibit DC 
migration in CD47-deficient mice, these effects were 
due to DC-expressed CD47 and through negative 
signaling via e.g. SIRPα ligation. In addition, entry 
of CD47-/- DCs into the marginal zone of the spleen 
was impaired, with a reduced number of DCs in the 
splenic marginal zone in CD47-deficient mice 
(Hagnerud et al., 2006). Of note, the injection of 
CD47+/+ DCs but not CD47-/- DCs triggered efficient 
T-cell priming in CD47-/- mice, demonstrating that 
DC-expressed CD47 is crucial (Van et al., 2006). 
Thus, signaling through the intracellular CD47 
domain on DCs is needed for efficient migration and 
entry of DCs to lymphoid organs. On neutrophils 
CD47 appears to be similarly important for 
migration, with blocking anti-CD47 mAbs delaying 
neutrophil transmigration and the rate of migration 
correlating with neutrophil surface-expressed CD47 
(Parkos et al., 1996; Liu et al., 2001). Thus, CD47 
expressed on DCs and neutrophils is required to 
efficiently induce immune responses. The role of 
CD47 signaling on DCs and neutrophils in anti-
cancer immune responses has not been evaluated yet, 
but will need to be taken into account when 
therapeutic targeting of CD47 is to be considered. 
Therapeutic targeting of CD47 activity in cancer 
immunity 
CD47, a multi-facetted target for cancer immunotherapy Wiersma VR, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(6) 422 
 
The therapeutic potential of targeting the 
immunoregulatory role of CD47 has been mainly 
investigated in the context of its anti-phagocyte 
activity (figure 3A) with a series of studies using 
monoclonal antibodies that disrupt CD47/SIRPα 
interaction. Anti-CD47 monoclonal antibody (mAb) 
B6H12 inhibited in vivo outgrowth and 
dissemination of xenotransplanted solid tumors and 
metastatic leiosarcoma as well as primary human 
NHL (Chao et al., 2011b; Willingham et al., 2012; 
Edris et al., 2012) (figure 3B). Further, in vivo 
outgrowth of human leukemia cells was inhibited by 
either CD47 or SIRPα blocking antibodies (Jaiswal 
et al., 2009; Majeti et al., 2009; Chao et al., 2011a). 
This therapeutic effect required macrophage effector 
cells since clonodrate depletion of macrophages 
abrogated any response (Jaiswal et al., 2009; Majeti 
et al., 2009; Chao et al., 2011a). Nevertheless, the 
mechanism of CD47 antibody-mediated in vivo 
tumor depletion remains debated. Specifically, the 
dominant therapeutic mode-of-action of intact CD47 
antibodies may be antibody dependent cellular 
cytotoxicity (ADCC) and FcR-dependent 
phagocytosis instead of disruption of CD47/SIRPα 
interaction (figure 3B). Indeed, injection of murine 
anti-CD47 mAb clone MIAP410 that does not affect 
CD47/SIRPα interaction (Han et al., 2000) also 
significantly inhibits tumor growth in immune 
competent mice (Willingham et al., 2012). 
Nevertheless, inhibition of CD47/SIRPα interaction 
alone can potentiate phagocytosis since CD47 
targeted F(ab')2 fragments did induce phagocytosis 
of NHL cells by mouse macrophages in vitro (Chao 
et al., 2010a), whereas rituximab derived F(ab')2 
fragments did not induce phagocytosis (figure 3C). 
Further, treatment of transgenic mice lacking SIRPα 
inhibitory signaling (by deletion of its cytoplasmic 
domain) with suboptimal concentrations of an anti-
melanoma therapeutic antibody (mAb TA99) 
yielded effective anticancer activity, indicating that 
SIRPα-derived negative signaling limits antibody-
mediated phagocytic elimination of target cells in 
vivo (figure 3D) (Zhao et al., 2011). Thus, the 
activity of anti-CD47 blocking antibodies may partly 
be attributed to blocking of the CD47 don't eat me 
signal but perhaps for a large part also due to typical 
antibody effector functions upon binding to tumor-
overexpressed CD47. Interestingly, in the above-
described SIRPα-signaling deficient mouse model, 
tumor outgrowth was not affected in the absence of 
therapeutic antibody, indicating that relieving 
CD47/SIRPα signaling is not sufficient for 
elimination of cancerous cells (Zhao et al., 2011; 
Zhao et al., 2012; Soto-Pantoja et al., 2012) (figure 
3D). Based on these data, the blocking of the CD47 
anti-phagocytic signal may only effectively elicit 
phagocytosis of target cells when combined with a 
prominent pro-phagocytic (therapeutic antibody) 
signal (Chao et al., 2010b). Preclinical data support 
this premise, with for instance anti-CD47 mAb 
blocking or CD47 knockdown in SKBR3 breast 
cancer cells potentiating the cytotoxicity of anti-Her-
2 antibody trastuzumab (Zhao et al., 2011).  
 
Figure 3: Therapeutic targeting of CD47 activity in cancer immunity. A. The interaction of CD47 (over) expressed on cancer 
cells with signal regulatory protein α (SIRPα) on phagocytes results in inhibition of phagocytosis. B. The use of full anti-CD47 
antibodies (containing an Fc-domain) prevents the interaction of CD47 with SIRPα, whereby phagocytosis is restored. This is 
also partly mediated by induction of ADCC via the Fcdomain of the antibody. The addition of a therapeutic antibody enhances 
the pro-phagocytic effect of anti-CD47 blockage. C. The use of F(ab')2 fragments of the anti-CD47 antibody (lacking the Fc-
domain) showed efficacy in some studies, whereas others showed the requisite for the presence of a complete functional 
antibody. The addition of a therapeutic antibody enhanced the therapeutic effect of F(ab')2 fragment-mediated CD47-blockage. 
D. Disrupting the CD47/SIRPα signaling pathway by expressing a signaling deficient form of SIRPα (by deletion of its 
cytoplasmic domain), was not sufficient to eliminate cancer cells in mice. However, when these SIRPα-signaling deficient mice 
were treated with an therapeutic antibody, this yielded effective anticancer activity. 
 
Moreover, combination treatment of NHL cells with 
rituximab and anti-CD47 potentiated their in vivo 
phagocytosis and elimination compared to rituximab 
alone (figure 3B) (Chao et al., 2011a). This 
synergistic enhancement also took place when an 
anti-CD47 F(ab')2 was co-administered with 
rituximab (Chao et al., 2011a) (figure 3C). Thus, 
probably the most effective use of releasing the 
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brake on the immune response by blocking CD47 is 
in the context of combinatorial treatment with a 
therapeutic anti-cancer antibody. 
Challenges to CD47-targeting in cancer immune 
evasion 
From the above it appears straightforward that the 
CD47/SIRPα interaction and reverse CD47 signaling 
in immune cells are prominent target for antibody-
based approaches. However, there are a few open 
questions that remain to be addressed. First, several 
reports suggest CD47 can also function as an "eat 
me" signal in certain circumstances. For instance, a 
subset of old erythrocytes present in whole blood 
was shown to bind and to be phagocytosed via 
CD47-SIRPα interactions (Burger et al., 2012). 
Moreover, CD47/SIRPα interaction was shown to 
promote engulfment of apoptotic splenocytes by 
BAM3 macrophages (Tada et al., 2003). 
Transformation with CD47 also augmented 
phagocytosis of a CD47 negative lymphoma cell line 
after the induction of apoptosis. Similarly, trans-
interaction of CD47 and SIRPα resulted in 
endocytosis of ligand-receptor complex by SIRPα-
expressing cells (Kusakari et al., 2008). Second and 
as also discussed earlier, CD47 can bind to SIRPβ2 
(Piccio et al., 2005). The SIRPβ subfamily comprises 
SIRPβ1 and SIRPβ2 and has a short intracellular 
domain of only a few amino acids (e.g. 4 for 
SIRPβ1). Despite this short domain, SIRPβ family 
members can transmit signals, with e.g. a positively 
charged lysine in the transmembrane domain of 
SIRPβ1 mediating interactions with an 
immunoreceptor tyrosine-based activation motif 
(ITAM) containing adaptor protein. Of note, 
whereas SIRPβ1 does not bind to CD47 (Seiffert et 
al., 2001), interaction of SIRPβ2 on CD3-positive T-
cells with endothelial CD47 is required for human T-
cell trans-endothelial migration (Stefanidakis et al., 
2008). Further, SIRPβ2 ligation by CD47 expressed 
on antigen-presenting cells induces T-cell 
proliferation (Piccio et al., 2005). Therefore, the use 
of CD47 blocking antibodies may also affect T-cell 
responses, e.g. by negatively regulating tumor-
infiltration of T-cells. Finally, it will be important to 
assess whether such CD47 antibodies have any 
effect on DC or T-cell activity through activation of 
reverse CD47 signaling. Of note, on DCs this CD47 
signaling is required for migration and should thus 
be activated. In contrast, on T-cells the major effect 
of CD47 signaling appears to be inhibitory with 
induction of T-cell arrest and promotion of 
regulatory T-cell differentiation and should thus be 
inhibited. If and how to reconcile these various 
requisites is an outstanding question. 
Anti-angiogenic and direct anti-
cancer effects mediated by CD47 
CD47 does not only affect the (cancer) immune 
response at various levels, but can also directly affect 
cancer cell biology and (neo)vascularization, i.e. 
tumor growth. Many of these effects can be 
attributed to interaction of tumor cell or endothelial 
cell-expressed CD47 with TSP-1. Thus, the 
CD47/TSP-1 axis represents an important tumor-
suppressor pathway in cancer and is a prominent 
target for therapeutic intervention. 
CD47/TSP-1 mediated anti-angiogenic activity 
The inhibition of angiogenesis is one of the best 
studied effects of CD47/TSP-1 and is due to TSP-1 
mediated modulation of endothelial cell adhesion, 
migration and proliferation (Lawler and Lawler, 
2012). Indeed, vascular outgrowth of explants from 
melanoma cells grown in TSP-1 knock-out mice in 
type I collagen matrices was better compared to 
explants derived from wildtype animals (Isenberg et 
al., 2008). Exogenous addition of TSP-1 to TSP-1-/- 
melanoma explants reduced vascular outgrowth to 
levels comparable to wildtype explants. Reversely, 
cutaneous squamous cell carcinoma cells that 
overexpressed TSP-1 had a decreased tumor vessel 
number and size in mice (Streit et al., 1999). 
Similarly, overexpression of TSP-1 reduced 
vascularization in spontaneous mammary tumors, 
whereas vascularization was significantly increased 
in TSP-1 deficient mice (Rodriguez-Manzaneque et 
al., 2001). The anti-angiogenic effects of TSP-1 were 
initially attributed to its binding to endothelial-
expressed CD36 (Dawson et al., 1997). Specifically, 
native TSP-1 bound to surface immobilized CD36, 
an interaction that was blocked by anti-angiogenic 
TSP-1 peptides (Dawson et al., 1997). However, in 
three-dimensional collagen cultures, the anti-
angiogenic effect of exogenous TSP-1 was 
abrogated in CD47-/- cells, but retained in CD36-/- 
cells (Isenberg et al., 2006), with ligation of CD36 
also failing to inhibit NO-stimulated proliferation in 
CD47-/- cells. Furthermore, anti-angiogenic effects 
of TSP-1 were inhibited by a TSP-1 peptide that 
recognizes CD47, leading to inhibition of vascular 
outgrowth in TSP-1 wildtype muscle explants. 
Similarly, TSP-1 peptide-mediated ligation of CD47 
was sufficient to inhibit NO-stimulated vascular cell 
responses. In line with this, overexpression of TSP-
1 by tumor cells decreases tumor blood flow in 
response to NO in vivo, which was abrogated in mice 
expressing a truncated TSP-1 lacking affinity for 
CD47 (Isenberg et al., 2008). Importantly, inhibitory 
signaling of TSP-1 via CD47 takes place at relevant 
physiological levels of TSP-1 (picomolar range), 
whereas TSP-1 mediated inhibitory signaling via 
CD36 requires higher concentrations of TSP-1 
(nanomolar range) (Isenberg et al., 2006). Thus, 
TSP-1 mediated inhibition of angiogenesis is 
regulated via interactions with both CD36 and 
CD47, whereby CD47 likely acts downstream of 
CD36 in endothelial signaling. Therefore, CD47 is 
the dominant anti-angiogenic receptor for TSP-1 
mediated inhibition of angiogenesis (figure 4A). 
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CD47 mediated regulation of angiogenesis via 
VEGFR-2 
In addition to the above-described TSP-1/CD47-
mediated inhibition of blood vessel formation, CD47 
directly interacts with VEGFR-2 on endothelial cells 
(Kaur et al., 2010). This direct interaction between 
CD47 and VEGFR-2 was demonstrated using 
immunofluorescent co-localization analysis and co-
immunoprecipitation. The association of CD47 with 
VEGFR was abrogated by TSP-1 or TSP-1 derived 
peptides that bind to CD47, but not by CD36 binding 
peptides. Furthermore, TSP-1 binding to CD47 
prevented phosphorylation of VEGFR-2 and its 
downstream target Akt (Kaur et al., 2010). Thus by 
binding to CD47, TSP-1 prevents CD47/VEGFR 
interaction and subsequent downstream signaling. In 
addition, TSP-1 itself also directly interacts with 
VEGF, thereby preventing angiogenic 
VEGF/VEGFR interaction (Gupta et al., 1999). In 
line with this, knockdown of TSP-1 increased the 
association of VEGF with VEGFR in spontaneous 
murine mammary tumors (Rodriguez-Manzaneque 
et al., 2001). Thus, the anti-angiogenic effect of TSP-
1 is also partly due to disturbing VEGF/VEGFR 
interaction either directly by binding to VEGF or by 
inhibition of CD47/ VEGFR interaction, an 
interaction crucial for downstream signaling (figure 
4A). 
Direct anti-cancer effects via cross linking of 
tumor expressed CD47 
The engagement of cancer cell-expressed CD47 by 
soluble TSP-1 strongly inhibited in vitro growth of a 
panel of breast cancer cell lines or pro-myelocytic 
leukemia cells through induction of caspase-
independent cell death (Saumet et al., 2005; Manna 
and Frazier, 2004). In breast cancer cell lines, cell 
death induction by CD47 requires Gi-mediated 
inhibition of protein kinase A (Manna and Frazier, 
2004). Similarly, B-cell chronic lymphocytic 
leukemia cells undergo caspase-independent cell 
death dependent on cytoskeletal reorganization upon 
treatment with soluble TSP-1 or anti-CD47 antibody 
(Mateo et al., 1999; Mateo et al., 2002) (figure 4B). 
Of note, TSP-1 or a CD47-blocking peptide reduced 
cell viability and in vivo growth of cells expressing 
oncogenic RAS, but did not affect immortalized 
nontumorigenic parental cells (Kalas et al., 2013). 
This tumoricidal activity of TSP-1 was dependent on 
CD47 cross-linking and activation of cytotoxic 
autophagy. These experimental results are in line 
with the near complete loss of TSP-1 expression in 
RAS-transformed cells. TSP-1/CD47 interaction can 
also differentially affect cancer cell sensitivity 
toward chemotherapeutics. For instance, TSP-1 
sensitized taxol-resistant prostate cancer cells to 
taxol treatment (Lih et al., 2006), whereas a blocking 
anti-CD47 antibody decreases cytotoxicity of taxol 
treatment. Of note, taxol resistance is partly 
regulated by the txr1 gene, a gene known to down-
regulate TSP-1 expression. Correspondingly, 
treatment with a TSP-1 mimetic peptide sensitized 
cells to taxol by activating CD47 signaling (Lih et 
al., 2006). In contrast, treatment of thyroid 
carcinoma cells with a CD47-binding peptide 
reduced doxorubicin and camtothecin cytotoxicity 
(Rath et al., 2006).  
In line with this, pro-apoptotic activity of 
camtothecin and doxorubicin relied on down-
regulation of TSP-1 expression in thyroid carcinoma 
(Rath et al., 2006). Therefore, the effect of TSP-
1/CD47-signaling on apoptosis is likely dependent 
on cancer type as well as type of therapy. In this 
respect, blocking of either CD47 or TSP-1 increased 
radiosensitivity of tumors, whereas it induced 
radioprotection in normal endothelial cells 
(Maxhimer et al., 2009).  
Although the mechanism of this differential response 
between normal and transformed cells is unknown, 
the in vitro suppression of CD47 did not increase the 
sensitivity of melanoma cells to radiation. Therefore, 
it was hypothesized that the observed enhanced anti-
tumor effects were due to induction of tumor-
specific immune responses. Thus, although cancer 
cells often up-regulate CD47 expression to escape 
from the immune system presumably via SIRPα-
mediated inhibitory signaling, cancer cells may also 
benefit from loss of expression of CD47. In this 
respect, loss of CD47 expression was also found to 
up-regulate c-Myc, induce cell proliferation and 
upregulate the self-renewal potential of endothelial 
cells (Kaur et al., 2013). 
Correspondingly, treatment with TSP-1 or the TSP-
1 derived peptide 7N3, inhibited c-Myc expression 
in Jurkat cells, but did not effect c-Myc expression 
in CD47-/- cells (Kaur et al., 2013). In contrast, the 
use of the TSP-1 derived peptide enhanced 
proliferation in human astrocytoma cell lines via an 
Akt-dependent pathway (Sick et al., 2011). 
Taken together, CD47-signaling via binding to TSP-
1 is involved in both tumorigenic as tumoricidal 
processes, although the latter seem to be the most 
prevalent outcome. 
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Figure 4: Anti-angiogenic and direct anti-cancer effects mediated by CD47. A. TSP-1 inhibits angiogenesis via binding to 
CD36 and CD47. However, TSP-1 mediated inhibition of angiogenesis by binding to CD36 is also regulated via CD47. In 
addition, CD47 directly interacts with vascular endothelial growth factor receptor-2 (VEGFR-2) on endothelial cells. By binding to 
CD47, this interaction is abrogated by TSP-1, whereby angiogenesis is inhibited. Further, TSP-1 can directly bind to VEGF, 
thereby preventing its interaction with VEGFR-2. B. Crosslinking of CD47 by antibodies or TSP-1 can lead to caspase-
independent cancer cell death. 
 
 
Therapeutic exploitation of CD47-mediated anti-
angiogenic and direct anti-cancer effects 
Based on the above, the therapeutic exploitation of 
CD47/TSP-1 interaction might prevent or reduce 
angiogenesis and tumor progression through both 
anti-angiogenic and possibly direct anti-cancer 
effects. Proof of concept for the former mechanism 
has been generated using a synthetic peptide, 
designated ABT-510, that mimics the anti-
angiogenic activity of TSP-1. ABT-510 treatment 
significantly increased the number of patients with 
stable disease in patients with advanced solid 
malignancy (12 different types of advanced cancer, 
including colorectal cancer, non-small-cell-lung 
cancer, renal cell cancer and sarcoma) (Hoekstra et 
al., 2005). Further, ABT-510 was well tolerated 
without significant toxicity in phase I trials upon 
subcutaneous application in patients with advanced 
stages of solid cancer (Gordon et al., 2008). 
However, minimal antitumor activity was detected 
in various phase II clinical trials including in 
advanced renal cell carcinoma (Ebbinghaus et al., 
2007), metastatic melanoma (Markovic et al., 2007) 
and advanced soft tissue sarcoma (Baker et al., 
2008). Optimization of peptide design may be used 
to further increase efficacy, as evidenced by a 
comparative study in dogs where better responses 
were detected with the second-generation TSP-1 
peptide ABT-898 (Sahora et al., 2012). However, 
most anti-angiogenic agents are best suited in 
combinatorial strategies with e.g. chemotherapeutics 
(Ma and Waxman, 2008). In line with this, ABT-510 
increased the uptake and effectiveness of cisplatin 
and paclitaxel in a mouse model of epithelial ovarian 
cancer (Campbell et al., 2010). Further, combination 
treatment with ABT-510 and bevacizumab 
prolonged the duration of stable disease in patients 
with advanced solid tumors (Uronis et al., 2013). 
Thus, blocking of TSP-1/CD47 interaction e.g. using 
anti-CD47 antibodies, in further combination with 
anti-angiogenic and chemotherapeutic regimens may 
well have clinical potential. However, clinical 
application of this strategy will need to take into 
account that tumors can upon prolonged exposure 
eventually by-pass anti-angiogenic effects of TSP-1 
(Filleur et al., 2001). In this respect, an optimal 
CD47-targeted strategy would provide a dual hit 
approach that would trigger not only anti-angiogenic 
activity but also direct CD47-mediated anti-cancer 
signaling that would sensitive cells for combinatorial 
strategies such as standard-of-care 
chemo/radiotherapy. 
Conclusions and perspectives 
CD47 is a prominent target for cancer therapy and 
has three main effects that should be considered in 
the design of CD47-based cancer therapy. The first 
and perhaps most studied effect is the inhibitory 
effect on anti-cancer immunity, which occurs 
through overexpression of CD47 on tumor cells and 
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inhibition of phagocytes through SIRPα binding 
(figure 5A).  
The second effect of CD47 is its reverse signaling 
activity through neutrophil, DC, or T-cell expressed 
CD47 that can both inhibit and activate immune 
responses. Finally, CD47 has direct anti-cancer and 
anti-angiogenic activity through its interaction with 
TSP-1 (figure 5B).  
All of these different aspects have to be carefully 
characterized for each malignancy and possibly in 
each patient using appropriately identified predictive 
biomarkers for CD47-based immunotherapy.  
Therapeutic anti-CD47 antibodies have shown 
promising pro-phagocytic activity in preclinical 
models. Further integration of CD47-targeting into 
bi-functional immunotherapeutics that combine 
CD47 blockade with alternate effector moieties may 
help to expand on this therapeutic effect. In this 
respect, we recently described an anti-CD47:TRAIL 
fusion protein that both induced phagocytosis via 
CD47 inhibition as well as induced CD47-restricted 
cell death in malignant B-cells (Wiersma et al., 
2014) (figure 5C). In an analogous fashion, it would 
be interesting to evaluate whether a bispecific 
antibody comprising a CD47 blocking antibody 
fragment and antibody fragment targeting a tumor 
overexpressed antigen could trigger tumor-localized 
accretion and inhibition of negative 
immunoregulatory signaling by CD47. Further, an 
approach combining both the anti-angiogenic effects 
of e.g. TSP-1 peptides and the pro-phagocytic 
activity of anti-CD47 mAbs may yield synergistic 
direct and immunostimulatory effects. 
Finally, CD47 overexpression in cancer can also be 
targeted with siRNA or miRNAs that down-regulate 
CD47.  
The potential of such an approach is highlighted by 
the delivery of liposome encapsulated CD47 siRNA, 
which effectively inhibited melanoma outgrowth 
and metastasis (Wang et al., 2013), whereas CD47-
targeted siRNA or shRNA treatment reduced 
migration of colon cancer cells (Broom et al., 2009; 
Zhang et al., 2013) and prevented in vivo 
dissemination of Non-Hodgkin lymphoma cells 
(Chao et al., 2011b).  
Finally, the transfection or injection of miR-133a, 
known to regulate CD47 expression, into mouse 
tumor xenografts significantly inhibited tumor 
outgrowth (Suzuki et al., 2012; Dong et al., 2013). 
Thus, siRNA or miRNA-mediated down-regulation 
of CD47 is a potentially interesting approach, which 
will however need to be performed using tumor-
selective delivery systems in order to prevent 
systemic side-effects. In conclusion, many different 
therapeutic strategies that target CD47 have already 
proven effective in preclinical models.  
The next few years are likely to witness the 
translation of CD47-targeting approaches into the 
clinic.  
This may hinge on development of strategies that 
have increased the tumor-selectivity of CD47 
blocking as well as identification of optimal 
combinatorial strategies with e.g. standard 
chemo/radiotherapy or combined triggering of anti-
angiogenic TSP-1 signaling. 
 
Figure 5: Perspectives in CD47-targeted cancer therapy. A. Blocking CD47/SIRPα signaling by use of anti-CD47 antibodies 
is effective, especially when combined with other therapeutic antibodies. B. Inhibition of angiogenesis via TSP-1/CD47 mediated 
signaling has potent anti-cancer effects. Combining the enhancement of phagocytosis and inhibition of angiogenesis would be of 
interest. C. Combining CD47 blockade with alternate effector moieties may help to expand on the therapeutic effect of this 
approach. In this respect, the anti-CD47:TRAIL fusion protein induced phagocytosis via CD47 inhibition, especially when 
combined with therapeutic antibodies, as well as induced CD47-restricted cell death in malignant B-cells. 
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